(redirected from antigen receptor)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
Related to antigen receptor: monoclonal antibody
See: receiver
Mentioned in ?
References in periodicals archive ?
Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019) [oral presentation].
DelveInsight Report, "PD-1 and PD-L1 inhibitors and Chimeric Antigen Receptor (CAR)-T cell Immunotherapy - Competitive Landscape, Pipeline and Market Analysis, 2015" gives the comprehensive insights on the PD-1 and PD-L1 Inhibitors and CART Immunotherapy.
The future is now: Chimeric antigen receptors as new targeted therapies for childhood cancer.
B-cell activation by cross-linking the B-cell antigen receptor, CD40-CD40L interactions to promote switching, TGF-bd1 by directing the switch to IgA, and Th2-type cytokines by increasing the number of post-switch Ig[A.
This high false-negative rate likely occurs because of the inability of consensus V primers to recognize complementary DNA sequences in all of the V segments and because of the inability of V and J primers to recognize genetic alterations such as partial rearrangements (DJ rearrangements) and chromosomal translocations and somatic mutations involving the antigen receptor gene loci [14,18].
Rapid, automated, closed system for transfection of Chimeric Antigen Receptor mRNA into T cells results in enhanced anti-tumor responses
CAB proteins can be generated in several different formats including naked monoclonal antibodies (mAbs), antibody drug conjugates, immune checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor (CAR) T cells.
New York (USA) and Suresnes (France) Cellectis and Servier today announced that they signed an amendment to their existing collaboration agreement from February 2014 especially for UCART19, a TALEN gene-edited allogeneic Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy.
com)-- DelveInsight, the leading Business Consultant and Market Research firm is pleased to declare the launch of its report, Chimeric Antigen Receptor (CAR)-T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2015.
Global & USA Cancer Immunotherapy Market Analysis to 2020 is a 2015 research report that provides information on Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Checkpoint Inhibitors, Adopted Cell Therapy (ACT) and IDO Inhibitors.
The alliance was formalized through an exclusive research and licensing agreement to further study and commercialize novel cellular immunotherapies using chimeric antigen receptor (CAR) technologies.
The modified T cells used in this study express an engineered fusion protein - called a chimeric antigen receptor - that combines the specificity of an antibody with the T cell signalling portions from two different proteins that stimulate the immune system to recognize ovarian cancer cells.